SPI Pharma and Inimmune, have created a strategic collaboration to develop and commercialize advanced adjuvant systems for vaccine development. The collaboration leverages Inimmune's world-class expertise in adjuvant formulation and immunotherapeutics and SPI Pharma's extensive manufacturing and global commercial capabilities.

Partnering with Inimmune:

Inimmune is a leader in the discovery and development of vaccine adjuvants with over 20 years of expertise in their safe and effective use. Inimmune’s novel small molecule adjuvants can activate the immune system in specific ways to drive the right immune response to deliver protection against pathogens of interest. Our lead vaccine adjuvants target innate immune receptors TLR4, TLR7/8, and Mincle and are focused on generating Th1 and Th17 responses. We are also working on discovering new adjuvants that target STING as well as inflammasome-activating adjuvants. Additionally, our formulations team has extensive expertise in tailoring vaccine delivery systems for these innate immune agonists, to match the route of administration and dosing required for a given indication.

Read Press Release

Dedication to Innovation and New Technology

We are expanding our portfolio to offer advanced vaccine systems and explore additional technologies. Our strategy is to advance new vaccine development with these materials.